Aventis Pasteur Limited
Lyons, FR· latest recorded location
Aventis Pasteur Limited is named on 22 US grants and 11 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 22
- Published applications
- 11
- Inventors
- 35
- Granted in 2026 so far
- 0
- Most recent grant
- 13 Nov 2012
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 2 | 0 |
| 2003 | 5 | 4 |
| 2004 | 4 | 2 |
| 2005 | 1 | 3 |
| 2006 | 3 | 0 |
| 2007 | 0 | 0 |
| 2008 | 3 | 0 |
| 2009 | 0 | 1 |
| 2010 | 3 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
By publication year.
Technology areas
Share of 33 documents
- A61KMedicines and medical preparations29
- C12NMicroorganisms or enzymes17
- A61PTherapeutic uses of medicines16
- C07KPeptides15
- Y02ATechnologies for adaptation to climate change7
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3
- B29CShaping or joining of plastics2
- C08BPolysaccharides2
- C12MApparatus for enzymology or microbiology1
- G01NInvestigating or analysing materials by determining their chemical or physical properties1
Recent patents
- Nucleic acids and polypeptides specific of the Neisseria genus pathogenic strains13 Nov 2012US 8,309,100 B2
- Conjugates obtained by reductive amination of the pneumococcus serotype 5 capsular polysaccharide12 Oct 2010US 7,812,006 B2
- Vaccine composition3 Aug 2010US 7,767,658 B2
- Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus27 Apr 2010US 7,704,513 B2
- Multivalent vaccine composition having increased stability of capsular polysaccharide29 Jul 2008US 7,404,960 B2
- Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains22 Jul 2010US 2010/0184639 A1
- Nucleic acids and polypeptides specific for pathogenic strains of the neisseria genus18 Jun 2009US 2009/0155886 A1
- Vaccine composition22 Sep 2005US 2005/0208060 A1
- Pharmaceutical composition for immunization against AIDS2 Jun 2005US 2005/0118188 A1
- Nucleic acids and polypeptides specific for pathogenic strains of the Neisseria genus10 Feb 2005US 2005/0032103 A1
Most cited
By later US patents
- Polysaccharide-peptide-conjugates45US 6,472,506 B12002
- Adjuvant for a vaccine composition38US 6,780,421 B12004
- Immunostimulant emulsion34US 6,610,308 B12003
- Method for the reductive amination of polysaccharides18US 6,596,861 B12003
- Vaccine composition for preventing or treating hepatitis C16US 6,538,123 B22003